肝转移瘤对放疗和丙亚胺的反应。
Responses of liver metastases to radiotherapy and razoxane.
作者信息
Hellmann K, Goold M, Higgins N, Phillips R H
机构信息
Radiotherapy Department, Westminister Hospital, London.
出版信息
J R Soc Med. 1992 Mar;85(3):136-8.
Twenty-five patients with liver metastases, chiefly due to colorectal cancer, were given a loading dose of razoxane for 3 days before 5 consecutive days of radiotherapy to the whole liver. Patients also took razoxane during the radiotherapy and then for one month afterwards. Liver tumour volume was measured on CT scans using the ELSCINT 3D soft tissue imaging programme just before and 4 weeks after the end of radiotherapy treatment. Twelve of the 25 patients had tumour volume reductions of more than 50%. The overall major response rate therefore is 12/25 (48%). In two of the major responders the liver metastases were due to recurrent stomach cancer. In addition to the 12 responders, four patients had a reduction of more than 20% but less than 50%, thus giving an overall response rate of 16/25 (64%). These results can form the basis of a formal, randomized, controlled clinical trial of radiotherapy alone (or any other treatment) compared with radiotherapy and razoxane in the difficult and life threatening condition presented by liver metastases.
25例主要因结直肠癌导致肝转移的患者，在对全肝进行连续5天放疗前，先接受3天的丙亚胺负荷剂量治疗。患者在放疗期间也服用丙亚胺，之后再服用1个月。在放疗结束前及结束后4周，使用ELSCINT 3D软组织成像程序通过CT扫描测量肝肿瘤体积。25例患者中有12例肿瘤体积缩小超过50%。因此，总体主要缓解率为12/25（48%）。在两名主要缓解者中，肝转移是由复发性胃癌引起的。除了这12名缓解者外，还有4名患者肿瘤体积缩小超过20%但小于50%，因此总体缓解率为16/25（64%）。这些结果可以作为在肝转移这种困难且危及生命的情况下，对单纯放疗（或任何其他治疗）与放疗联合丙亚胺进行正式、随机、对照临床试验的基础。
Zotero 插件